A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

PLoS One · 2011 · PMC3176224 · PMID 21949716

Europe PMC DOI

hedged sentence

0.0450

closest p · 0.9× alpha

0.0450

boldest claim

The sentences

did not reach statistical significanceP = 0.045actually significant

Median 3D7 MSP2 IgG levels were consistently higher in cohort 2 compared to cohort 1 at all time points ( Figure 2 ; Table 4 ), although this did not reach statistical significance except at day 168 for which there was some evidence of increased 3D7 MSP2 responses in cohort 2 compared to cohort 1 (P = 0.045).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.